Search results for: Pricing and Reimbursement
Filter search results
Reflections from Adrian Towse on decades of HEOR research and impact
11 November 2025
…Pay for something else and you will get something else. Hence my motivation in writing and arguing for value-based pricing as a means of putting the static and dynamic pieces…
Around The World in HTAs: Greece – Late but with an Optimistic Future
18 October 2023
…The regulatory framework for the authorisation, pricing, and reimbursement of pharmaceutical products falls within the scope of Ministerial and Interministerial decisions on pharmaceutical products. It should be noted that the…
Around The World in HTAs: The Netherlands – 5 Routes for New Tech
24 May 2023
…Netherlands, Luxembourg, Austria and Ireland is the BeNeLuxA initiative, which aims to improve collaboration on pharmaceutical policy and procurement by means of horizon scanning, HTA, information sharing and policy exchange,…
Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool
9 September 2024
…Thailand’s HTA agency, the Health Intervention and Technology Assessment Program (HITAP), and HTA has since become a requirement before making reimbursement decisions for the UCS. The other two schemes, CSMBS and SSS,…
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
…be low. Benefits and weaknesses of TEVs and of the European Commission’s proposals The TEV proposal has been controversial and we set out the arguments for and against drawing on…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
…OHE Briefing on the topic of multi-indication pricing. The briefing contains a summary of a workshop organised and facilitated by OHE and MME Europe. Multi-indication pricing (MIP) involves setting a…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…In reality, indication launches within a country can be costly, with significant investment needed in regulatory and HTA submission and compliance, manufacturing and distribution adjustments, marketing and commercialisation, and any…
A Spotlight on Haemophilia Therapies
3 October 2024
…bodies must foster a supportive policy environment that recognises and rewards innovation, including intellectual property protection, transparent approval requirements and processes, and pricing and reimbursement policies that incentivise and reward…
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
…development of combination therapies becoming more common in oncology and beyond, and a lack of agreed-upon pricing models in Europe, the need for innovative pricing strategies is increasingly evident. The…